JIANGXI FUSHINE PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10 CNY | +5.26% |
|
+26.90% | +6.84% |
| 28/04 | Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 19/02 | Fushine Pharma's Unit Gets Nod for Tazobactam Sodium | MT |
| Sales 2022 | 1.65B 228M 19B | Sales 2023 | 1.61B 223M 18.56B | Capitalization | 5.04B 697M 58.15B |
|---|---|---|---|---|---|
| Net income 2022 | -141M -19.5M -1.63B | Net income 2023 | -201M -27.79M -2.32B | EV / Sales 2022 | 4.55 x |
| Net Debt 2022 | 390M 53.92M 4.5B | Net Debt 2023 | 895M 124M 10.33B | EV / Sales 2023 | 3.69 x |
| P/E ratio 2022 |
-50.8
x | P/E ratio 2023 |
-25.3
x | Employees | 2,179 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.76% |
More Fundamentals
* Assessed data
More news
| 1 day | +5.26% | ||
| 1 week | +26.90% | ||
| Current month | +7.41% | ||
| 1 month | +6.84% | ||
| 3 months | +22.85% | ||
| 6 months | -2.82% | ||
| Current year | +6.84% |
1 week
8.00
10.10
1 month
7.4410.10
Current year
5.6210.10
1 year
5.6214.33
3 years
5.6229.40
5 years
5.6229.40
10 years
3.2929.40
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Hua Bao
CEO | Chief Executive Officer | 47 | 01/12/01 |
Guang Yang
DFI | Director of Finance/CFO | 37 | 01/09/01 |
Rong Wu Cheng
BRD | Director/Board Member | 55 | 01/04/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yan Li
BRD | Director/Board Member | 67 | 01/15/01 |
Jian Hua Bao
CEO | Chief Executive Officer | 47 | 01/12/01 |
Wei Dong
BRD | Director/Board Member | 46 | 01/12/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 10 | +5.26% | 13 770 630 |
| 26/24/26 | 9.5 | +5.32% | 13,177,050 |
| 25/24/25 | 9.02 | +4.28% | 7,207,900 |
| 24/24/24 | 8.65 | +6.00% | 7,075,232 |
| 23/24/23 | 8.16 | +1.37% | 3,820,100 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Jiangxi Fushine Pharmaceutical Co., Ltd. is principally engaged in research and development, manufacturing and sales of bulk drugs, pharmaceutical intermediates and related products. The Company's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The Company distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.84% | 706M | |
| +25.93% | 661B | |
| +26.74% | 566B | |
| -6.65% | 352B | |
| +19.38% | 332B | |
| +3.37% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.15% | 145B |
- Stock Market
- Equities
- 300497 Stock
